Meta-analysis of efficacy,safety and immunogenicity of adalimumab biosimilars and original drugs in the treatment of rheumatoid arthritis
Objective:To systematically evaluate the efficacy,safety and immunogenicity of aldamumab bioanalogues and aldamumab antigenics in the treatment of rheumatoid arthritis.Methods:By searching the databases in Chinese and English,randomized controlled studies that were inclusive and exclusive to the criterias were screened,and the data were extracted.After the quality of the included studies was evaluated by the bias risk assessment tool,the RevMan 5.4.1 statistical software is used for Meta analysis.Results:A total of 14 studies regarding 10 biosimilar drugs were included,with a total of 6 933 RA patients.The results showed that there was no significant difference in ACR20 and the positive rate of anti-drug antibody between the two groups.Compared with the total number of adverse reactions in the two groups,statistical differences are found.The total number of adverse reactions and serious adverse reactions in the trial group is lower than that of the control group.The results of the subgroup analysis show that there is no statistical difference.Conclusion:The efficacy and immunogenicity of adamumab biosimilars in the treatment of rheumatoid arthritis are equivalent to the original drug,and safe as the original drug.
NETL
NSTL
万方数据
